To provide the information your oncologist is not telling you or doesn't have the time to!
Embark on a focused exploration of Stomach Cancer within our dedicated subcategory. Tailored to provide insights into the complexities of this gastric malignancy, our ‘Stomach Cancer’ section offers a comprehensive understanding. Navigate through informative articles, expert perspectives, and the latest advancements in research and treatment options specific to stomach cancer. Whether you’re seeking information on early detection, treatment modalities, or strategies for managing the unique challenges associated with stomach cancer, our subcategory serves as a reliable resource. Empowering individuals, caregivers, and healthcare professionals, we aim to foster awareness and understanding to navigate the complexities of stomach cancer. Join us on a journey toward informed decision-making and proactive gastric health within this specialized arena of oncology
Radiation therapy has long been a cornerstone in the treatment of various cancers, including gastric cancer, particularly for locally advanced or high-risk cases. However, the evolving landscape of gastric cancer management has raised questions about the necessity of adding preoperative chemoradiotherapy to standard perioperative chemotherapy. The recently published TOPGEAR trial sheds new light on this …
On October 18, 2024, the U.S. Food and Drug Administration (FDA) approved zolbetuximab-clzb (Vyloy, Astellas Pharma), a novel treatment for adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. This approval brings a much-needed new option for patients whose tumors express the CLDN18.2 protein, as identified through an FDA-approved test. …
On November 7, 2023, the Food and Drug Administration (FDA) made significant updates to the existing indication of pembrolizumab (Keytruda, Merck) for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. These changes come as part of the FDA’s commitment to advancing cancer treatment options, bringing …
Article written by one of our Melanoma/Sarcoma Clinical Trial Coordinators Chloe Caldwell to a target audience of healthcare providers regarding a new ongoing protocol for patients dealing with GIST open globally and at the Orlando Health Cancer Institute. All information posted here is publicly available here. Gastrointestinal Stromal Tumors (GIST) constitute a category of soft …
Metastatic gastric cancer, also known as stage IV gastric cancer, is a serious and advanced form of the disease in which the cancer has spread beyond the stomach to other parts of the body. The current standard of care for patients with metastatic gastric cancer includes chemotherapy, Her2 targeted therapy and immunotherapy. However, there remains …
Gastric cancer, also known as stomach cancer, is a type of cancer that begins in the lining of the stomach. It is the fifth most common cancer and the third leading cause of cancer-related deaths worldwide. The incidence of gastric cancer varies by geographic region and population, with higher rates in Eastern Asia, South America, …